Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest

Authors: Julian J Raffoul, Yu Wang, Omer Kucuk, Jeffrey D Forman, Fazlul H Sarkar, Gilda G Hillman

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

New cancer therapeutic strategies must be investigated that enhance prostate cancer treatment while minimizing associated toxicities. We have previously shown that genistein, the major isoflavone found in soy, enhanced prostate cancer radiotherapy in vitro and in vivo. In this study, we investigated the cellular and molecular interaction between genistein and radiation using PC-3 human prostate cancer cells.

Methods

Tumor cell survival and progression was determined by clonogenic analysis, flow cytometry, EMSA analysis of NF-κB, and western blot analysis of cyclin B1, p21WAF1/Cip1, and cleaved PARP protein.

Results

Genistein combined with radiation caused greater inhibition in PC-3 colony formation compared to genistein or radiation alone. Treatment sequence of genistein followed by radiation and continuous exposure to genistein showed optimal effect. Cell cycle analysis demonstrated a significant dose- and time-dependent G2/M arrest induced by genistein and radiation that correlated with increased p21WAF1/Cip1 and decreased cyclin B1 expression. NF-κB activity was significantly decreased by genistein, yet increased by radiation. Radiation-induced activation of NF-κB activity was strongly inhibited by genistein pre-treatment. A significant and striking increase in cleaved PARP protein was measured following combined genistein and radiation treatment, indicating increased apoptosis.

Conclusion

A mechanism of increased cell death by genistein and radiation is proposed to occur via inhibition of NF-κB, leading to altered expression of regulatory cell cycle proteins such as cyclin B and/or p21WAF1/Cip1, thus promoting G2/M arrest and increased radiosensitivity. These findings support the important and novel strategy of combining genistein with radiation for the treatment of prostate cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer Statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130.CrossRefPubMed
2.
Zietman AL, Shipley WU, Willett CG: Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer. 1993, 71 (3 Suppl): 959-969.CrossRefPubMed
3.
Forman JD: Neutron radiation for prostate cancer. Prostate J. 1999, 1: 8-14. 10.1046/j.1525-1411.1999.00003.x.CrossRef
4.
Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, Rivlin R, Simopoulos A, Wargovich MJ, Weisburger EK, Zeisel SH: The role of dietary supplements during cancer therapy. J Nutr. 2003, 133: 3794S-3799S.PubMed
5.
Norman HA, Go VL, Butrum RR: Review of the international research conference on food, nutrition, and cancer, 2004. J Nutr. 2004, 134: 3391S-3393S.PubMed
6.
Knight DC, Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol. 1996, 87: 897-904.PubMed
7.
Mills R, Beeson W, Phillips R, Fraser G: Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer. 1989, 64: 598-604.CrossRefPubMed
8.
Giovannucci E: Epidemiologic characteristics of prostate cancer. Cancer. 1995, 75: 1766-1777.CrossRef
9.
Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT: Soybean phytoestrogen intake and cancer risk. J Nutr. 1995, 125: 757S-770S.PubMed
10.
Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995, 375: 577-581. 10.1038/375577a0.CrossRefPubMed
11.
Tatsuta M, Iishi H, Baba M, Yano H, Uehara H, Nakaizumi A: Attenuation by genistein of sodium chloride enhances gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1999, 80: 396-399. 10.1002/(SICI)1097-0215(19990129)80:3<396::AID-IJC10>3.0.CO;2-1.CrossRefPubMed
12.
Okura A: Effect of genistein on topoisomerase activity and on the cell growth of val[12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun. 1988, 157: 183-189. 10.1016/S0006-291X(88)80030-5.CrossRefPubMed
13.
Adlercreutz H: Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Investig. 1990, 201 (Suppl): 3-23.CrossRef
14.
Huang J, Nasr M, Kim Y, Matthews HR: Genistein inhibits protein histidine kinase. J Biol Chem. 1992, 267: 15511-15515.PubMed
15.
Sarkar FH, Li Y: The role of isoflavones in cancer chemoprevention. Front Biosci. 2004, 9: 2714-24.CrossRefPubMed
16.
Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I: Growth inhibitory effect of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer. 1994, 30: 1675-1682. 10.1016/0959-8049(94)00262-4.CrossRef
17.
Constantinou A, Huberman E: Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Proc Soc Exp Biol Med. 1995, 208: 109-115.CrossRefPubMed
18.
Kyle E, Neckers L, Takimoto C, Curt G, Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol. 1997, 51: 193-200.PubMed
19.
Spinnozi F, Pagliacci M, Migliorati G, Moraca R, Grignani F, Ricardi C, Nicoletti I: The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T leukemia cells. Leuk Res. 1994, 18: 431-439. 10.1016/0145-2126(94)90079-5.CrossRef
20.
Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene. 1999, 18: 3166-3172. 10.1038/sj.onc.1202650.CrossRefPubMed
21.
Li Y, Bhuiyan M, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol. 1999, 15: 525-533.PubMed
22.
Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH: Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer. 1999, 34: 12-19. 10.1207/S15327914NC340102.CrossRefPubMed
23.
Davis JN, Singh B, Bhuiyan M, Sarkar FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998, 32: 123-131.CrossRefPubMed
24.
Hillman GG, Forman JD, Kucuk O, Yudelev M, Maughan RL, Rubio J, Layer A, Tekyi-Mensah S, Abrams J, Sarkar FH: Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res. 2001, 7: 382-390.PubMed
25.
Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, Sarkar FH: Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther. 2004, 3: 1271-1279.PubMed
26.
Hillman GG: Experimental animal models for renal cell carcinoma. Tumor Models in Cancer Research. Edited by: Teicher BA. 2002, Totowa, NJ, Humana Press, 493-505.
27.
Hashimura T, Tubbs RR, Connelly R, Caulfield MJ, Trindade CS, McMahon JT, Galetti TP, Edinger M, Sandberg AA, Cin PD, Sait SJ, Pontes JE: Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res. 1989, 49: 7064-71.PubMed
28.
Raffoul JJ, Cabelof DC, Nakamura J, Meira LB, Friedberg EC, Heydari AR: Apurinic/apyrimidinic endonuclease (APE/REF-1) haploinsufficient mice display tissue-specific differences in DNA polymerase beta-dependent base excision repair. J Biol Chem. 2004, 279: 18425-33. 10.1074/jbc.M313983200.CrossRefPubMed
29.
Davis JN, Kucuk O, Sarkar FH: Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer. 1999, 35: 167-174. 10.1207/S15327914NC352_11.CrossRefPubMed
30.
Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004, 59: 928-42. 10.1016/j.ijrobp.2004.03.005.CrossRefPubMed
31.
Geldof AA, Plaizier MA, Duivenvoorden I, Ringelberg M, Versteegh RT, Newling DW, Teule GJ: Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol. 2003, 129: 175-82.PubMed
32.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366: 701-4. 10.1038/366701a0.CrossRefPubMed
33.
Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994, 9: 2261-8.PubMed
34.
El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol. 2001, 3: E71-3. 10.1038/35060148.CrossRefPubMed
35.
Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991, 51: 4716-20.PubMed
36.
Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000, 92: 376-387. 10.1093/jnci/92.5.376.CrossRefPubMed
37.
Yan S-X, Ejima Y, Sasaki R, Zheng S-S, Demizu Y, Soejima T, Sugimura K: Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Asian J Androl. 2004, 6: 285-290.PubMed
38.
Yashar CM, Spanos WJ, Taylor DD, Gercel-Taylor C: Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol Oncol. 2005, 99: 199-205. 10.1016/j.ygyno.2005.07.002.CrossRefPubMed
39.
Lin A, Karin M: NF-kappaB in cancer: a marked target. Semin Cancer Biol. 2003, 13: 107-114. 10.1016/S1044-579X(02)00128-1.CrossRefPubMed
40.
Yamamoto Y, Gaynor RB: Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med. 2001, 1: 287-296. 10.2174/1566524013363816.CrossRefPubMed
41.
Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002, 2: 301-310. 10.1038/nrc780.CrossRefPubMed
42.
Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L: Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res. 2004, 10: 5501-5507. 10.1158/1078-0432.CCR-0571-03.CrossRefPubMed
43.
Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S: Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia. 2004, 6: 390-400.CrossRefPubMedPubMedCentral
44.
Li Y, Ellis KL, Ali S, El-Rayes B, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH: Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-κB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004, 28: e90-e95. 10.1097/00006676-200405000-00020.CrossRefPubMed
45.
Ozeki M, Tamae D, Hou DX, Wang T, Lebon T, Spitz DR, Li JJ: Response of cyclin B1 to ionizing radiation: regulation by NF-kappaB and mitochondrial antioxidant enzyme MnSOD. Anticancer Res. 2004, 24: 2657-63.PubMedPubMedCentral
46.
Wuerzberger-Davis SM, Chang PY, Berchtold C, Miyamoto S: Enhanced G2-M arrest by nuclear factor-κB-dependent p21waf1/cip1 induction. Mol Cancer Res. 2005, 3: 345-53. 10.1158/1541-7786.MCR-05-0028.CrossRefPubMed
47.
Li Y, Ahmad F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65: 6934-42. 10.1158/0008-5472.CAN-04-4604.CrossRefPubMed
48.
Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65: 9064-9072. 10.1158/0008-5472.CAN-05-1330.CrossRefPubMed
49.
Davis DA, Sarkar SH, Hussain M, Li Y, Sarkar FH: Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer. 2006, 6: 22-10.1186/1471-2407-6-22.CrossRefPubMedPubMedCentral
50.
Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH: Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer. 2006, 106: 1260-1268. 10.1002/cncr.21731.CrossRefPubMed
Metadata
Title
Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest
Authors
Julian J Raffoul
Yu Wang
Omer Kucuk
Jeffrey D Forman
Fazlul H Sarkar
Gilda G Hillman
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-107

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators

Research article

Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma

Research article

Association between dietary fat and skin cancer in an Australian population using case-control and cohort study designs

Research article

FGFR1 and WT1 are markers of human prostate cancer progression

Research article

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

Research article

A non-randomised, single-centre comparison of induction chemotherapy followed by radiochemotherapy versus concomitant chemotherapy with hyperfractionated radiotherapy in inoperable head and neck carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits